EUVIMEDEUVIMED entdecken
Crossref

Insights Into the Mechanism of Action for Qingzhi Decoction for the Treatment of Non‐Alcoholic Fatty Liver Disease via Regulation of the IRS/PI3K/Akt Signaling Pathway and the NRLP3 Inflammasome

Jiejun Yan iD, Qian Hou, Jing Liu, Weilan Li

Biomedical Chromatography · 2025

DOI: 10.1002/bmc.70156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Jiejun Yan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Zhongda Hospital Southeast University, Nanjing, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Drugs, Chinese Herbal, Signal Transduction, Inflammasomes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Jiangsu Pharmaceutical Association-Zhengda Tianqing Hospital Pharmaceutical Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The objective of this study is to explore the impacts of Qingzhi Decoction (QZT) in Non‐alcoholic fatty liver disease (NAFLD) mice induced by a high‐glucose and high‐fat diet. UPLC‐Orbitrap‐Exploris MS characterized 156 bioactive components in QZT. Subsequently, an NAFLD model was established in ICR mice via 8‐week feeding with a high‐glucose and high‐fat diet. The NAFLD mice were randomly divided into four groups. After 8 weeks of drug administration, compared with the control group, the model group showed significant NAFLD‐related liver pathological changes, manifested as elevated blood lipid parameters (TC, TG, and LDL) and decreased HDL. Liver injury markers (ALT and AST) and serum inflammatory cytokines (IL‐1β, IL‐6, and TNF‐α) were significantly increased. Molecular analysis indicated that the expression of p‐IRs‐1, PI3K, and p‐Akt was decreased in liver tissue, while the expression of SREBP, NLRP3, caspase1, and GSDMD was increased. QZT treatment alleviated these changes, significantly improving NAFLD pathology, normalizing lipid profiles, and regulating the expression of these molecular markers ( p < 0.01). QZT improved insulin resistance, regulated lipid metabolism, and reduced inflammatory response, and its mechanism might be associated with the regulation of IRs‐1 and NLRP3 pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseDrugs, Chinese HerbalSignal TransductionInflammasomesAnimalsMiceMaleMice, Inbred ICRProto-Oncogene Proteins c-aktLiverPhosphatidylinositol 3-KinasesInsulin Receptor Substrate ProteinsDisease Models, AnimalDiet, High-FatNLR Family, Pyrin Domain-Containing 3 Protein

Stichwörter der Autor:innen

IRs/PI3K/AktNLRP3Qingzhitanginflammatory reactionnon‐alcoholic fatty liver disease

Substanzen

Drugs, Chinese HerbalInflammasomesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesInsulin Receptor Substrate ProteinsIrs1 protein, mouseNLR Family, Pyrin Domain-Containing 3 Protein

Autor:innen und Institutionen

  • Department of Pharmacy, Zhongda Hospital Southeast University, Nanjing, China.
  • Internal Medicine Department of Traditional Chinese Medicine, Zhongda Hospital Southeast University, Nanjing, China.

ORCID-Profile: Jiejun Yan

Förderung

  • Jiangsu Pharmaceutical Association-Zhengda Tianqing Hospital Pharmaceutical Research Fund

Zitieren

APA

Yan, J., Hou, Q., Liu, J., & Li, W. (2025). Insights Into the Mechanism of Action for Qingzhi Decoction for the Treatment of Non‐Alcoholic Fatty Liver Disease via Regulation of the IRS/PI3K/Akt Signaling Pathway and the NRLP3 Inflammasome. Biomedical Chromatography. https://doi.org/10.1002/bmc.70156

Vancouver

Yan J, Hou Q, Liu J, Li W. Insights Into the Mechanism of Action for Qingzhi Decoction for the Treatment of Non‐Alcoholic Fatty Liver Disease via Regulation of the IRS/PI3K/Akt Signaling Pathway and the NRLP3 Inflammasome. Biomedical Chromatography. 2025. doi:10.1002/bmc.70156

BibTeX
@article{Yan2025,
  author = {Yan, Jiejun and Hou, Qian and Liu, Jing and Li, Weilan},
  title = {Insights Into the Mechanism of Action for Qingzhi Decoction for the Treatment of Non‐Alcoholic Fatty Liver Disease via Regulation of the IRS/PI3K/Akt Signaling Pathway and the NRLP3 Inflammasome},
  journal = {Biomedical Chromatography},
  year = {2025},
  doi = {10.1002/bmc.70156}
}
Kostenlos starten →